ArticleScientific reports2026
Preoperative assessment of axillary lymph node tumor burden in cT1-2N0 breast cancer patients with a modality-adaptive network based on sentinel lymph node ultrasound images.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
To determine a direct method for diagnosing axillary lymph node (ALN) tumor burden preoperatively in cT1-2N0 breast cancer patients, we developed and validated a deep learning (DL) model based on ultrasound (US) images of sentinel lymph nodes (SLNs) detected by contrast-enhanced lymphatic ultrasound (CEUS). Women with cT1-T2N0 breast cancer who received CEUS were enrolled prospectively from Peking Union Medical College Hospital between April 2020 and July 2021 and from Sichuan Cancer Hospital between April 2022 and July 2022. Heavy ALN tumor burden was defined as > 2 metastatic lymph nodes according to the Z0011 criteria. We developed a DL model, the modality-adaptive network with clinicopathological information (MAN + C), using grayscale or color Doppler US images and radioclinicopathological information to predict heavy tumor burden. A total of 595 SLNs from 374 patients met the inclusion criteria. The areas under the receiver operating characteristic curve (AUCs) were calculated to evaluate the predictive performance of the model, yielding values of 0.91[95%CI(confidence interval):0.899-0.943], 0.98[95%CI:0.950-1], 0.89[95%CI:0.850-0.935], and 0.84[95%CI:0.811-0.869] in the training, validation, independent and external test datasets, respectively. Compared to current artificial intelligence (AI) models, this model extends usability by 30%, encompassing patients with multifocal lesions or those who have undergone primary breast cancer lesion therapy. Using this model, 88.9% of patients could safely decide whether they could waive unnecessary SLN biopsy. MAN + C provided a direct and efficient method for accurate preoperative assessment of ALN tumor burden in cT1-2N0 breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.